Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital

2015 ◽  
Vol 39 (1) ◽  
pp. 55-62
Author(s):  
E. S. Mendoza ◽  
A. A. Lopez ◽  
V. A. U. Valdez ◽  
E. C. Cunanan ◽  
B. J. Matawaran ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Tertiary Hospital ◽  
Response To Therapy ◽  
Papillary Thyroid ◽  
Incomplete Response

scholarly journals Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy

2020 ◽  
Vol 9 (8) ◽  
pp. 2481
Author(s):  
Kirk Jensen ◽  
Shilpa Thakur ◽  
Aneeta Patel ◽  
Maria Cecilia Mendonca-Torres ◽  
John Costello ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Liquid Biopsy ◽  
Digital Pcr ◽  
Response To Therapy ◽  
Response To Treatment ◽  
Papillary Thyroid ◽  
Primary Tumors ◽  
Promising Tool ◽  
Increased Risk

The detection of rare mutational targets in plasma (liquid biopsy) has emerged as a promising tool for the assessment of patients with cancer. We determined the presence of cell-free DNA containing the BRAFV600E mutations (cfBRAFV600E) in plasma samples from 57 patients with papillary thyroid cancer (PTC) with somatic BRAFV600E mutation-positive primary tumors using microfluidic digital PCR, and co-amplification at lower denaturation temperature (COLD) PCR. Mutant cfBRAFV600E alleles were detected in 24/57 (42.1%) of the examined patients. The presence of cfBRAFV600E was significantly associated with tumor size (p = 0.03), multifocal patterns of growth (p = 0.03), the presence of extrathyroidal gross extension (p = 0.02) and the presence of pulmonary micrometastases (p = 0.04). In patients with low-, intermediate- and high-risk PTCs, cfBRAFV600E was detected in 4/19 (21.0%), 8/22 (36.3%) and 12/16 (75.0%) of cases, respectively. Patients with detectable cfBRAFV600E were characterized by a 4.68 times higher likelihood of non-excellent response to therapy, as compared to patients without detectable cfBRAFV600E (OR (odds ratios), 4.68; 95% CI (confidence intervals)) 1.26–17.32; p = 0.02). In summary, the combination of digital polymerase chain reaction (dPCR) with COLD-PCR enables the detection of BRAFV600E in the liquid biopsy from patients with PTCs and could prove useful for the identification of patients with PTC at an increased risk for a structurally or biochemically incomplete or indeterminate response to treatment.

Response to therapy of papillary thyroid cancer of known BRAF status

2017 ◽  
Vol 87 (6) ◽  
pp. 815-824 ◽  
Author(s):  
Aldona Kowalska ◽  
Agnieszka Walczyk ◽  
Artur Kowalik ◽  
Iwona Pałyga ◽  
Danuta Gąsior-Perczak ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Response To Therapy ◽  
Papillary Thyroid

scholarly journals Risk Factor Stratification of Lung Metastasis in Children and Adolescent Papillary Thyroid Cancer

2021 ◽  
Author(s):  
Liying Wang ◽  
Feng Liu ◽  
Lingyun Zhang ◽  
Shu Rui ◽  
Yang Liu ◽  
...  
Keyword(s):  
Risk Factor ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Lung Metastasis ◽  
Independent Risk Factor ◽  
Significant Risk ◽  
Response To Therapy ◽  
Papillary Thyroid ◽  
Children And Adolescent ◽  
Factors Associated

Abstract Background: Lung metastasis (LM) in pediatric papillary thyroid cancer (pPTC) is significantly higher than in adults. While spare information about pPTC and LM hampers to formulate specific guideline. Hence, we retrospectively analyzed the whole pPTCs in our center to investigate factors associated with LM and therapy outcomes.Materials and Methods: PTCs with age＜20 years who received initial operations in ourcenterfrom December 2008 to December 2018 were retrospectively reviewed. Clinicopathological information, treatment pipelineand outcomes were analyzed retrospectively.Results:Totally, 114 pPTC patients were enrolled in our study, LM was observed in 17 (14.9 %) cases. Significant risk factors associated with LM were age, sex, tumor size, multifocality, extrathyroidal extension, lymph node metastasis, number of metastatic lymph nodes (NMLNs)and postoperative stimulated thyroglobulin (sTg). NMLNs ＞14 was identified as an independent risk factor for LM by multivariate analysis (OR 25.166, 95% CI 2.814 - 225.009, p = 0.004) with a sensitivity of 86.7% and specificity of 81.1% for LM, which was verified by integrated meta-analysis. In terms ofresponse to radioiodine treatment in LM, 2 cases reached ‘‘excellent’’ response. ‘‘Biochemically incomplete’’, ‘‘structurally incomplete’’ and “indeterminate” were in 3,12, 2 of 17 patients respectively. Postoperative sTg was correlated with the response to therapy of LM in pPTCs(p = 0.003).Conclusion: LM was frequently observed in pPTCs. NMLNs ＞14 was an independent risk factor for LM in our study and other cohorts, and postoperative sTg was a potential predictor for the therapy outcome of LM in pPTCs.

scholarly journals Blood prognostic predictors of treatment response for patients with papillary thyroid cancer

2020 ◽  
Vol 40 (10) ◽  
Author(s):  
Xiangxiang Liu ◽  
Zhongke Huang ◽  
Xianghui He ◽  
Xiangqian Zheng ◽  
Qiang Jia ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Poor Prognosis ◽  
Response To Therapy ◽  
Prognostic Indicators ◽  
High Morbidity ◽  
American Thyroid Association ◽  
Papillary Thyroid ◽  
Distribution Width ◽  
Prognosis Group

Abstract Background: Papillary thyroid cancer (PTC) is a very common malignant disease with high morbidity. We needed some pretreatment indicators to help us predict prognosis and guide treatment. We conducted a study about some pretreatment prognostic indicators. Methods: This clinical study recruited 705 postoperative PTC patients (211 males, 494 females). Clinical data before radioactive iodine (RAI) treatment were collected. Patients’ response to therapy were classified into two categories: ‘Good Prognosis Group’ (GPG) and ‘Poor Prognosis Group’ (PPG), according to ‘2015 American Thyroid Association Guidelines’. Differences of indicators between different prognosis groups were compared. Odds ratios (ORs) were calculated by univariate/multiple binary logistic regression models. Difference of body mass index (BMI) changes before and after RAI treatment between different prognosis groups was also compared. Results: A total of 546 (77.45%) belonged to GPG, and 159 (22.55%) belonged to PPG. Platelet (PLT), neutrophil (NEUT), PLT subgroups, and combination of red blood cell distribution width (RDW) and BMI (COR-BMI) were different between two prognosis groups. The significance of the difference between the two groups of BMI disappeared after the Bonferroni correction. PLT and PLT subgroups had detrimental effects on the risk of PPG; T stage had a positive effect on the risk of PPG. PLT subgroup showed a detrimental effect on the risk of PPG when we included additional covariates. Conclusions: We found that lower pretreatment PLT levels may indicate a poor prognosis for PTC. The relationship between platelet-derived growth factor (PDGF) and radiation sensitivity may be the key to this association.

Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy

2017 ◽  
Vol 24 (9) ◽  
pp. 2611-2616 ◽  
Author(s):  
Nicole K. Zern ◽  
Roderick Clifton-Bligh ◽  
Anthony J. Gill ◽  
Ahmad Aniss ◽  
Stan Sidhu ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Disease Progression ◽  
Papillary Thyroid Cancer ◽  
Initial Therapy ◽  
Papillary Thyroid ◽  
Incomplete Response

scholarly journals Blood-Rich Enhancement in Ultrasonography Predicts Worse Prognosis in Patients With Papillary Thyroid Cancer

2021 ◽  
Vol 10 ◽  
Author(s):  
Luying Gao ◽  
Xuehua Xi ◽  
Qiong Gao ◽  
Jiajia Tang ◽  
Xiao Yang ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cox Regression ◽  
Area Under The Curve ◽  
Papillary Thyroid ◽  
Predictive Values ◽  
Incomplete Response ◽  
Potential Association ◽  
Contrast Enhanced ◽  
Patient Prognosis

Contrast-enhanced ultrasound (CEUS) can be used to evaluate microcirculation in cancers, which in turn is associated with the biologic features and ultimately patient prognosis. We conducted a retrospective analysis to examine potential association between CEUS parameters and prognosis in patients with papillary thyroid cancer (PTC). The analysis included 306 patients who underwent CEUS prior to thyroidectomy at our center during a period from 2012 to 2019. Subjects with excellent response (ER) were compared to the non-ER group (including indeterminate response, biochemical incomplete response and structural incomplete response). During the median follow-up of 34 months, ER was observed in 195 (63.7%) subjects. The remaining 111 (36.3%) patients developed non-ER events, with distant metastasis in five (1.6%) cases. In a multivariate COX regression, non-ER event was associated with the male sex (OR = 1.83, 95%CI: 1.21–2.76) and blood-rich enhancement in CEUS (OR = 1.69, 95%CI: 1.04–2.75). Based on this finding, we developed a predictive model: high risk for developing non-ER events was defined as having both risk factors; low risk was defined as having none or only one risk. In receiver operating characteristic (ROC) analysis, the area under the curve was 0.59 (95%CI: 0.52–0.66). The sensitivity and specificity were 17.1 and 95.4%, respectively. The positive and negative predictive values were 67.9 and 66.9%, respectively. In conclusion, blood-rich enhancement in CEUS is associated with non-ER events after thyroidectomy in patients with PTC.

scholarly journals Nomogram for the Prediction of Biochemical Incomplete Response in Papillary Thyroid Cancer Patients

2021 ◽  
Vol Volume 13 ◽  
pp. 5641-5650
Author(s):  
Seung Taek Lim ◽  
Ye Won Jeon ◽  
Hongki Gwak ◽  
Ja Seong Bae ◽  
Young Jin Suh
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Incomplete Response

scholarly journals Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2563
Author(s):  
Sena Turkdogan ◽  
Marc Pusztaszeri ◽  
Veronique-Isabelle Forest ◽  
Michael P. Hier ◽  
Richard J. Payne
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Thyroid Nodules ◽  
Molecular Genetic ◽  
Hospital Setting ◽  
Retrospective Chart Review ◽  
Tertiary Hospital ◽  
P Value ◽  
Papillary Thyroid ◽  
Genetic Test Results

The Bethesda classification system for thyroid fine needle aspirate (FNA) is used to predict the risk of malignancy and to guide the management of thyroid nodules. We postulated that thyroid malignancies characterized as Bethesda III on FNA have more aggressive features than those classified as Bethesda IV. A retrospective chart review was performed to identify those who underwent thyroid surgery at a single tertiary hospital setting between 2015 and 2020. Associations between Bethesda category, molecular genetic test results, and histopathologic findings were examined. Out of 628 surgeries that were performed, 199 (54.2%) Bethesda III nodules and 216 (82.8%) Bethesda IV nodules were malignant. Of those that were malignant, 37 (18.6%) and 22 (10.2%) Bethesda III and Bethesda IV nodules showed aggressive features, respectively (p value = 0.014). There was a proportionally increased number of aggressive features in extra-thyroidal extension, lymph nodes metastasis, and all aggressive subtypes of papillary thyroid cancer in the Bethesda III category. Although Bethesda IV nodules are much more likely to be malignant (p value = 0.002), our study suggests that Bethesda III nodules that are resected are more likely to have aggressive features than Bethesda IV nodules, with a statistically significant increase in the solid variant of papillary thyroid cancer and lymph node metastasis.

scholarly journals Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer?

2021 ◽  
Vol 10 (11) ◽  
pp. 2438
Author(s):  
Aleksandra Gajowiec ◽  
Anna Chromik ◽  
Kinga Furga ◽  
Alicja Skuza ◽  
Danuta Gąsior-Perczak ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Predictive Factor ◽  
Disease Status ◽  
Initial Therapy ◽  
Clinicopathological Features ◽  
Response To Therapy ◽  
Papillary Thyroid ◽  
Male Sex

Identifying risk factors is crucial for predicting papillary thyroid cancer (PTC) with severe course, which causes a clinical problem. The purpose of this study was to assess whether male sex can be such a predictive factor and to verify whether including it as a predictive factor of high initial risk of recurrence/persistence would help to enhance the value of the American Thyroid Association initial risk stratification system (ATA). We retrospectively analyzed 1547 PTC patients (1358 females and 189 males), treated from 1986 to 2018. The relationship between sex and clinicopathological features, response to therapy, and disease status was assessed. Men with PTC showed some adverse clinicopathological features more often than women, including angioinvasion, lymph node metastases, and tumor size > 40 mm. There were sex-related disparities with respect to response to initial therapy and final follow-up. Male sex is associated with some unfavorable clinicopathological features of PTC, which may affect response to initial therapy or final disease status. In our study, modification of the ATA system by including male sex as a risk factor does not enhance its value. Thus, further studies are needed to assess whether males require treatment modalities or oncological follow-up protocols that are different from those of females.

Sign in / Sign up

Export Citation Format

Share Document